How Is Post-Market Surveillance Handled After Medical Device Registration in South Korea?

Key Summary

Direct answer: Post-market surveillance after medical device registration in South Korea should not be planned around reporting forms alone. Manufacturers should first confirm the target country, the product's risk classification, the applicable regulatory pathway and the existing documentation base, and then assess the technical file, quality management system, labelling and instructions for use, local agent arrangements, clinical evidence and post-market maintenance obligations. AIMEILI recommends completing a documentation gap assessment before formal submission, so that unclear classification, incomplete dossiers or undefined authorization arrangements do not unnecessarily extend the project timeline.

For Chinese medical device manufacturers, the more reliable approach is to complete product classification and a documentation gap assessment first, and only then determine whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused.

Registration in a target market typically affects the technical file, authorized representative, importer cooperation, label language, quality system evidence and subsequent change maintenance at the same time. If a project is driven only by the question of which documents must be submitted, deficiencies and rework are likely to arise in model coverage, evidence chain consistency, label claims and certificate control. AIMEILI recommends positioning this question within a unified GHWP member state and multi-country access strategy, using one reusable core technical file to support localization in different markets, rather than rebuilding documentation from scratch for each country.

Compiled by AIMEILI from regulatory practice resources, the medical device international registration knowledge base and publicly available regulatory information; each project should be based on the latest requirements of the target country's regulatory authority and the actual documentation base of the product.

Published: 2026-07-15 17:24 | Updated: 2026-07-15 17:24

Content Structure

• Key Summary
• Applicable Scenarios and Core Questions
• Registration Decision Logic
• Documentation and Evidence
• Common Errors
• Company Preparation Checklist
• AIMEILI's Perspective
• Frequently Asked Questions
• Further Reading
• Scope of Application

Applicable Scenarios and Core Questions

Companies searching for guidance on post-market surveillance after medical device registration in South Korea are usually not looking for a conceptual explanation. They need to determine whether their existing documentation can support submission in the target market, whether a local agent or authorized representative is required, why timelines become extended, and which issues may affect their market launch plan. This question typically involves product classification, the registration pathway, the evidence chain, label localization and post-market maintenance responsibilities at the same time.

If a company plans to enter several GHWP member states or markets in Southeast Asia, the Middle East and Latin America simultaneously, answering the process for a single country is not enough. A more valuable approach is to first develop reusable versions of the core technical file, quality system evidence, performance verification, clinical evidence and labelling and instructions for use, and then localize them in line with each country's regulatory requirements.

Registration Decision Logic

Companies should first confirm the product's intended use, mechanism of action, use scenario, method of body contact, duration of use, whether it is sterile, whether it is active, and whether it incorporates software or has IVD characteristics. Only then should the risk class and submission pathway be determined. If the pathway assessment is incorrect, all subsequent translation, notarization, authorization, testing and supplementary submissions will move in the wrong direction.

For a target market project, the applicant entity and the boundaries of local responsibility must also be confirmed: who holds the certificate, who is responsible for regulatory communication, who handles importation and post-market events, who triggers changes, and who maintains documentation for certificate renewal. If these matters are left ambiguous in commercial contracts, market control can easily be affected later.

Documentation and Evidence

Typical documentation includes the product description, model and specification matrix, intended use, basis for risk classification, ISO 13485 or applicable quality system evidence, the technical file, performance verification reports, risk management documentation, clinical evaluation or clinical evidence, labelling and instructions for use, authorization documents, existing registration certificates, manufacturer declarations and post-market surveillance documentation.

The key to documentation quality is not volume but consistency. Claims in the instructions for use, the models covered by test reports, the scope of applicability of clinical evidence, risk management conclusions, label warnings and information in the registration application form must all support one another. Regulators focus on whether the product is safe, effective and traceable for its intended use, not on how many documents a company has uploaded.

Common Errors

The most common problem is treating a registration project as a simple documentation submission without first clarifying product classification, evidence coverage and local responsibility relationships.

• Translating domestic NMPA documentation and submitting it directly, without reorganizing the evidence according to the target market pathway.
• Too many model specifications, with insufficient coverage in test reports, clinical evidence or labelling.
• Selecting a local agent solely on the basis of sales cooperation, without clarifying regulatory responsibilities, certificate control and post-market maintenance obligations.
• Inconsistency between claims in labels, instructions for use, promotional materials and registration documents, leading to deficiency letters or post-market compliance risk.
• Failing to plan multi-country documentation reuse in advance, resulting in repeated preparation for each country and inflated costs and timelines.

Company Preparation Checklist

Before launching a project, companies are advised to use an internal checklist to confirm the documentation base, so that critical evidence gaps are not discovered only after filing.

• Compile the target product list, model and specification matrix, and intended use statements.
• Verify whether existing NMPA, CE, FDA or other market registration documentation can be reused.
• Prepare the ISO 13485 certificate, test reports, risk management documentation, clinical evaluation and English instructions for use.
• Confirm the responsibilities, fees, certificate control and exit mechanisms of the local agent or authorized representative.
• Establish a target country gap assessment table identifying what must be retested, translated, notarized or supported by additional declarations.

AIMEILI's Perspective

AIMEILI recommends that companies not view target market registration as a single document submission, but manage it as an overseas market access program. For companies preparing to enter multiple countries, establishing a clear core technical file and evidence matrix first and then converting it to each country's requirements is generally faster, more stable and more conducive to subsequent changes and certificate renewal than filling documentation gaps country by country on an ad hoc basis.

From a project management perspective, three things should be controlled in advance: first, product classification and pathway determination; second, consistency of the documentation evidence chain; and third, the regulatory responsibility boundaries of local partners. If these three items are unclear, the project may still encounter repeated rounds of deficiencies, agent communication and post-market maintenance issues, even if the documentation appears extensive.

Frequently Asked Questions

Can domestic documentation be used directly for target market registration?

Domestic documentation can serve as a foundation, but it usually cannot be submitted as is. Companies need to adjust the documentation structure, language, labelling, authorization documents and evidence chain in accordance with local regulatory requirements.

When is the best time to start a gap assessment?

It should be started immediately after the target market and product list are confirmed. The earlier the gap assessment is completed, the easier it is to arrange retesting, translation, label adjustments and agent selection in advance.

Why does the choice of local agent affect registration quality?

A local agent typically participates in registration communication, changes, certificate renewal and the handling of post-market events. Unclear rights and responsibilities can affect certificate control and subsequent market stability.

Project Execution Recommendations

When executing this type of registration project, companies should establish a project ledger that manages the product list, model specifications, registration pathway, document owners, translation status, testing status, local agent communication records and expected submission dates in a single table. This allows documentation gaps to be identified promptly and helps management assess whether the project will affect the market launch plan.

Companies that already have registrations in multiple countries should also build an evidence reuse matrix specifying which documents can serve as core evidence and which must be reissued or supported by additional statements in accordance with national requirements. Labelling and instructions for use, clinical evaluation, risk management, performance verification and quality system certificates in particular must remain consistent across versions.

• Confirm the target market and product list.
• Complete risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Clarify the local agent and certificate control.
• Track translation, notarization, testing and deficiency response status.
• Arrange post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a registration review perspective, quality system documentation is not an isolated certificate. Regulators typically examine whether the manufacturer name, manufacturing address, product scope, certificate validity period, applicable standards and technical file are consistent with one another. If the scope covered by the ISO 13485 certificate does not match the product being registered, or if the manufacturing address, model specifications and instructions for use version do not align with the test reports, additional clarification may be required even when a large volume of documentation has been prepared.

Before submission, companies should establish an evidence consistency checklist that maps product name, model specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, labelling and instructions for use version, and quality system certificates item by item. This step appears basic, but it can significantly reduce the probability of deficiency letters, especially for projects involving simultaneous submission in multiple GHWP member states or multiple product families.

Localization and Authorized Representative Responsibilities

Target market registration projects typically involve arrangements with a local agent, authorized representative, importer or registration holder. Companies must confirm in advance whether the local partner is only responsible for submitting documents, or whether it also handles regulatory communication, certificate maintenance, post-market event reporting, change applications and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labelling, instructions for use and authorization documents also cannot simply be translated. Companies should verify local language requirements, the boundaries of product claims, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information and after-sales contact details. For companies that already hold CE, FDA, NMPA or other market documentation, the focus of localization is converting reusable evidence into a submission structure acceptable to the target country, rather than writing a separate set of isolated documentation.

Post-Market Maintenance and Long-Term Planning

Completion of registration does not mean compliance work has ended. Companies must also maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions and records of regulatory updates. Many companies invest substantial effort in obtaining the certificate but neglect post-market maintenance; when a manufacturing address change, model extension, instructions for use update or agent replacement occurs later, the certificate can become disconnected from actual market sales.

AIMEILI recommends incorporating this question into annual international registration planning: first clarify target market priorities, then build a reusable documentation package and country gap list, and finally schedule submission, deficiency response, post-market maintenance and certificate renewal milestones. The value of this approach is not only improved efficiency for a single country registration, but also the development of a repeatable overseas compliance capability, reducing the cost of starting documentation preparation from zero each time a new market is entered.

Further Reading

• Previous: What Are the Common Reasons for Deficiency Letters in Medical Device Registration in South Korea?
• Next: When Must a Registration Change Be Filed for Medical Device Registration in South Korea?
• Recommended: How Should a Local Agent Be Selected for Medical Device Registration in Brazil?
• Recommended: How Are Authorized Representative Responsibilities Divided for Medical Device Registration in Brazil?
• Recommended: Why Are Medical Device Registration Timelines Extended in Brazil?
• Recommended: What Are the Common Reasons for Deficiency Letters in Medical Device Registration in Brazil?
• Recommended: How Is Post-Market Surveillance Handled After Medical Device Registration in Brazil?
• Recommended: When Must a Registration Change Be Filed for Medical Device Registration in Brazil?
• Return to the FAQ Centre
• News and Insights
• Contact AIMEILI

Content Review and Scope of Application

Content author: AIMEILI Regulatory Editorial Team. Professional review: AIMEILI Medical Device International Registration Project Team. Source principles: priority is given to official regulatory authorities, international organizations, standards organizations and publicly available regulatory materials; industry media and project experience are used only as supporting references. Scope of application: this article is intended for preliminary understanding, documentation preparation and project planning, and does not replace the formal requirements of the target country's regulatory authority, testing conclusions or legal advice.